NCT03937986View on ClinicalTrials.gov

Suvorexant and Cocaine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Cocaine Use Disorder
Interventions
DRUG

Suvorexant

The pharmacodynamic effects of suvorexant maintenance will be determined.

DRUG

Cocaine

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

DRUG

Placebo oral capsule

The pharmacodynamic effects of placebo will be determined.

Trial Locations (1)

40507

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

William Stoops

OTHER

NCT03937986 - Suvorexant and Cocaine | Biotech Hunter | Biotech Hunter